KPT-330-mediated XPO1 inhibition impairs homologous recombination and enhances radiosensitivity in extranodal NK/T-cell lymphoma
Open Access
- 16 June 2026
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 135 (6) , 1-11
Abstract
Background Extranodal NK/T-cell lymphoma (ENKTL) is a rare, aggressive lymphoma in which radioresistance remains a major cause of treatment failure in the relapsed/refractory (R/R) setting. Methods We analysed XPO1 expression in ENKTL and assessed its role in radiosensitization using monoallelic XPO1-knockout models and KPT-330 in vitro and in xenografts. Mechanistic studies focused on the c-Myc–RAD51/CHEK1 axis, and clinical efficacy was evaluated in two R/R patients. Results Immunohistochemistry showed XPO1 overexpression in primary treatment-naïve ENKTL specimens relative to nasal polyp controls, and high XPO1 expression was associated with inferior overall survival. Monoallelic XPO1 knockout impaired homologous recombination (HR) repair, establishing a DNA repair defect exploitable as a radiosensitizing vulnerability. Pharmacologic inhibition of XPO1 with KPT-330 recapitulated these HR defects and synergised with radiotherapy. Mechanistically, KPT-330 disrupts the XPO1–c-Myc–RAD51/CHEK1 axis by blocking c-Myc nuclear export, reducing c-Myc abundance and promoter occupancy at the RAD51 and CHEK1 loci, thereby impairing HR. In two heavily pretreated R/R ENKTL patients, radiotherapy rechallenge plus low-dose KPT-330 achieved one partial response and one complete response with manageable toxicity. Conclusions XPO1 inhibition impairs HR and enhances radiosensitivity by disrupting the c-Myc–RAD51/CHEK1 axis. These findings support prospective evaluation of KPT-330–based radiosensitization in R/R ENKTL. The alternative text for this image may have been generated using AI.Keywords
This publication has 27 references indexed in Scilit:
- Mechanisms and interventions in relapsed/refractory extranodal natural killer/T-cell lymphomaDrug Discovery Today, 2025
- The nuclear export receptor CRM1/XPO1 and its diverse cargoesTrends in Biochemical Sciences, 2025
- Unlocking the Radiosensitizing Potential of MYC Inhibition in Neuroendocrine MalignanciesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2025
- Excessive MYC-topoisome activity triggers acute DNA damage, MYC degradation, and replacement by a p53-topoisomeMolecular Cell, 2024
- MYC determines lineage commitment in KRAS-driven primary liver cancer developmentJournal of Hepatology, 2023
- Targeting Non-homologous and Alternative End Joining Repair to Enhance Cancer RadiosensitivitySeminars in Radiation Oncology, 2022
- Review on natural killer/T‐cell lymphomaHematological Oncology, 2021
- Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trialThe Lancet Haematology, 2020
- Biomarker-Guided Development of DNA Repair InhibitorsMolecular Cell, 2020
- A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-TypeEBioMedicine, 2017